Literature DB >> 15531497

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.

E O Talbott1, J V Zborowski, J R Rager, M Y Boudreaux, D A Edmundowicz, D S Guzick.   

Abstract

Women with polycystic ovary syndrome (PCOS) exhibit an adverse cardiovascular risk profile, characteristic of the metabolic cardiovascular syndrome (MCS). The aim of this study was to determine the prevalence of coronary artery (CAC) and aortic (AC) calcification among middle-aged PCOS cases and controls and to explore the relationship among calcification, MCS, and other cardiovascular risk factors assessed 9 yr earlier. This was a prospective study of 61 PCOS cases and 85 similarly aged controls screened in 1993-1994 for risk factors and reevaluated in 2001-2002. The main outcome measures were CAC and AC, measured by electron beam tomography. Women with PCOS had a higher prevalence of CAC (45.9% vs. 30.6%) and AC (68.9% vs. 55.3%) than controls. After adjustment for age and body mass index, PCOS was a significant predictor of CAC (odds ratio = 2.31; P = 0.049). PCOS subjects were also 4.4 times more likely to meet the criteria for MCS than controls. High-density lipoprotein cholesterol and insulin appeared to mediate the PCOS influence on CAC. Interestingly, total testosterone was an independent risk factor for AC in all subjects after controlling for PCOS, age, and body mass index (P = 0.034). We conclude that women with PCOS are at increased risk of MCS and demonstrate increased CAC and AC compared with controls. Components of MCS mediate the association between PCOS and CAC, independently of obesity.

Entities:  

Mesh:

Year:  2004        PMID: 15531497     DOI: 10.1210/jc.2003-032237

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  63 in total

Review 1.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

2.  Defining the role of bariatric surgery in polycystic ovarian syndrome patients.

Authors:  Shaveta M Malik; Michael L Traub
Journal:  World J Diabetes       Date:  2012-04-15

3.  Evidence of proatherogenic inflammation in polycystic ovary syndrome.

Authors:  Frank González; Neal S Rote; Judi Minium; John P Kirwan
Journal:  Metabolism       Date:  2009-07       Impact factor: 8.694

4.  Severity of aortic calcification is positively associated with vertebral fracture in older men--a densitometry study in the STRAMBO cohort.

Authors:  P Szulc; E J Samelson; E Sornay-Rendu; R Chapurlat; D P Kiel
Journal:  Osteoporos Int       Date:  2012-08-08       Impact factor: 4.507

Review 5.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 6.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

7.  Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome.

Authors:  Ekwutosi M Okoroh; Sheree L Boulet; Mary G George; W Craig Hooper
Journal:  Thromb Res       Date:  2015-10-17       Impact factor: 3.944

8.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

9.  Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome.

Authors:  Frank González; John P Kirwan; Neal S Rote; Judi Minium
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-12-18       Impact factor: 4.310

10.  Association of polycystic ovary syndrome and a non-dipping blood pressure pattern in young women.

Authors:  Ayse Kargili; Feridun Karakurt; Benan Kasapoglu; Aysel Derbent; Cemile Koca; Yusuf Selcoki
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.